Genovis’ Board of Directors has decided upon a private placement

        Print
| Source: Genovis AB
Following authorization by the Extraordinary General Meeting of November 19,
2013, Genovis’ Board of Directors has decided upon a private placement of a
maximum of 804,643 shares in the company. The subscription period runs until
January 20 and the subscription price is SEK 4.50, which is the same as in the
rights issue with the subscription period December 2 to 16, 2013.The issue will
raise a maximum of SEK 3.6 million for the company and share capital could
increase by a maximum of SEK 321,857.20. Following the completed private
placement, share capital will amount to a maximum of SEK 8,738,260.80 and the
number of shares will be a maximum of 21,845,652. The reason for deviation from
shareholders’ preferential rights is to be able to take advantage of interest
from underwriters within the framework of issued underwriting guarantees in the
rights issue with the subscription period December 2-16, 2013.

The issue will have a dilutive effect of about 3%.
For more information, please contact: Sarah Fredriksson, CEO, Genovis AB Tel: 46
(0)46 -101235 sarah.fredriksson@genovis.com
ABOUT GENOVIS

Genovis’ business concept is to develop, produce and market innovative
technologies that facilitate and enable development of new treatment methods and
diagnostics for customers in the medical device and pharmaceutical industries.
The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis
develops and sells unique enzymes (protein engineering portfolio) in innovative
product formats that facilitate development and quality control of and
biological drugs. GeccoDots uses nanotechnology to produce a new type of
contrast agent that is used in medical imaging.

Genovis shares are listed on NASDAQ OMX First North, and Thenberg Fondkommission
is Certified Adviser for the Company, t: 46 (0)31-745 50 00